Zhao Fei, Wen Duo, Zeng Lin, Wang Ruiqi, Wang Dingran, Xu Huiyu, Li Rong, Chi Hongbin
Department of Obstetrics and Gynecology, Center for Reproductive Medicine, Peking University Third Hospital, Beijing, 100191, China.
National Clinical Research Center for Obstetrics and Gynecology, Peking University Third Hospital, Beijing, 100191, China.
Reprod Biol Endocrinol. 2025 Jan 28;23(1):15. doi: 10.1186/s12958-025-01347-6.
To study the correlation between anti-Müllerian hormone levels and pregnancy outcomes after in vitro fertilization/intracytoplasmic sperm injection in women with polycystic ovary syndrome, which remains controversial.
This retrospective cohort study recruited 4,719 women with infertility and polycystic ovary syndrome aged 20-40 years who underwent treatment at the Reproductive Center of Peking University Third Hospital between February 2017 and June 2023. We divided the participants into three groups according to the 25th and 75th percentile cutoffs of serum anti-Müllerian hormone: low (≤ 4.98 ng/mL, n = 1,198), average (4.98 - 10.65 ng/mL, n = 2,346), and high (≥ 10.65 ng/mL, n = 1,175). Pregnancy outcomes included live birth rate, miscarriage rate, clinical pregnancy rate, and cumulative live birth rate.
The live birth rate for fresh embryo transfer was 39.8%, 35.9%, and 30.4% in the low, average, and high anti-Müllerian hormone groups, respectively. The miscarriage rate was 11.3%, 17.1%, and 21.8% in the low, average, and high anti-Müllerian hormone groups, respectively. Significant intergroup differences were observed in the live birth rate (P = 0.017) and miscarriage rate (P = 0.018). No significant intergroup difference was observed in the clinical pregnancy rate (P = 0.204) or cumulative live birth rate (P = 0.423). After adjusting the confounders by multivariable logistic regression analysis, anti-Müllerian hormone was associated with decreased live birth rate in the high anti-Müllerian hormone group compared with that in the low anti-Müllerian hormone group (odds ratio: 0.629, 95% confidence interval: 0.460-0.860). Anti-Müllerian hormone was associated with increased miscarriage rate in the average and high anti-Müllerian hormone groups compared with that in the low anti-Müllerian hormone group (average vs. low: odds ratio: 1.592, 95% confidence interval: 1.017-2.490); high vs. low: odds ratio: 2.045, 95% confidence interval: 1.152-3.633).
High anti-Müllerian hormone is a prognostic factor for reduced live birth rate after fresh embryo transfer in women with polycystic ovary syndrome aged 20-40 years undergoing in vitro fertilization/intracytoplasmic sperm injection, and is associated with increased miscarriage rate in these patients.
研究多囊卵巢综合征女性体外受精/卵胞浆内单精子注射后抗苗勒管激素水平与妊娠结局之间的相关性,这一相关性仍存在争议。
这项回顾性队列研究纳入了2017年2月至2023年6月期间在北京大学第三医院生殖中心接受治疗的4719例年龄在20 - 40岁的不孕且患有多囊卵巢综合征的女性。我们根据血清抗苗勒管激素的第25和第75百分位数临界值将参与者分为三组:低水平组(≤4.98 ng/mL,n = 1198)、中等水平组(4.98 - 10.65 ng/mL,n = 2346)和高水平组(≥10.65 ng/mL,n = 1175)。妊娠结局包括活产率、流产率、临床妊娠率和累积活产率。
在抗苗勒管激素低、中、高组中,新鲜胚胎移植的活产率分别为39.8%、35.9%和30.4%。流产率在抗苗勒管激素低、中、高组中分别为11.3%、17.1%和21.8%。活产率(P = 0.017)和流产率(P = 0.018)在组间存在显著差异。临床妊娠率(P = 0.204)和累积活产率(P = 0.423)在组间未观察到显著差异。通过多变量逻辑回归分析调整混杂因素后,与抗苗勒管激素低水平组相比,抗苗勒管激素高水平组的活产率降低(优势比:0.629,95%置信区间:0.460 - 0.860)。与抗苗勒管激素低水平组相比,抗苗勒管激素中等水平组和高水平组的流产率增加(中等水平组与低水平组相比:优势比:1.592,95%置信区间:1.017 - 2.490;高水平组与低水平组相比:优势比:2.045,95%置信区间:1.152 - 3.633)。
对于年龄在20 - 40岁接受体外受精/卵胞浆内单精子注射的多囊卵巢综合征女性,高抗苗勒管激素是新鲜胚胎移植后活产率降低的一个预后因素,并且与这些患者流产率增加相关。